Régis Costello

Inserm — France

Immunology and Microbiology · Life Sciences

41h-index5.7kcitations277works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(54), Chronic Lymphocytic Leukemia Research(53), Acute Myeloid Leukemia Research(47), Lymphoma Diagnosis and Treatment(33), T-cell and B-cell Immunology(29)

Publications275 total

Predicting the toxicity-efficacy ratio of venetoclax in real-world patients
Annals of Hematology·2025Open Access
Epcoritamab + GemOx achieves durable >2-year remissions in relapsed/refractory (R/R) 2L+ diffuse large B-cell lymphoma (DLBCL): Long-term data reinforce clinical potential of the regimen across a diverse patient population
Blood·2025Open Access
Anthracyclines induce epigenetic changes in ALDH1A that promote chemoresistance in AML, revealing a potential treatment strategy co-targeting ALDH1A inhibition with hypomethylating agents
Blood·2025Open Access
Upregulation of ALDH1 as an adaptive epigenetic response to anthracyclines in acute myeloid leukemia
HemaSphere·2025· 1 citedOpen Access
Assessment of Systematic <scp> <i>JAK2V617F</i> </scp> Screening in 996 Patients With Venous Thromboembolism
American Journal of Hematology·2025· 2 cited
Expression of Aldehyde Dehydrogenase 1A1 in Relapse-Associated Cells in Acute Myeloid Leukemia
Cells·2025· 1 citedOpen Access
SplenoMegaly study (SMS): exploring the etiologies for “unexplained” splenomegalies in the real world
Orphanet Journal of Rare Diseases·2025Open Access
Abstract 4362: Body mass index influences imatinib exposure in CML patients: Evidence fromTDM with adaptive dosing in real-world patients
Cancer Research·2025
Impact of CDA Dynamics on Clinical Outcome of Patients With AML or High‐Risk MDS Treated With Nucleoside Analogs
Hematological Oncology·2025Open Access
Author response for "Impact of CDA Dynamics on Clinical Outcome of Patients With AML or High‐Risk MDS Treated With Nucleoside Analogs"
2025
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial
Blood·2025· 36 citedOpen Access
Body mass index affects imatinib exposure: Real‐world evidence from TDM with adaptive dosing
Fundamental and Clinical Pharmacology·2025· 5 citedOpen Access
Body Mass Index influences Imatinib exposure in CML patients: evidence from TDM with adaptive dosing
SPIRE - Sciences Po Institutional REpository·2024Open Access
Odyssey: A First-in-Human Study of the Aldehyde Dehydrogenase (ALDH) Inhibitor Abd-3001 in Patients with Refractory/Relapsed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Blood·2024· 1 cited
Open-Label Phase 2 Study Results of FS118, a LAG-3/PD-L1 Bispecific Antibody, in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Blood·2024· 2 citedOpen Access
Reactive oxygen species and aldehyde dehydrogenase <scp>1A</scp> as prognosis and theragnostic biomarker in acute myeloid leukaemia patients
Journal of Cellular and Molecular Medicine·2024· 6 citedOpen Access
ABCL-275 Epcoritamab + GemOx Induces Deep Durable Responses in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Results From EPCORE NHL-2
Clinical Lymphoma Myeloma & Leukemia·2024
Epcoritamab + GemOx Induces Deep, Durable Responses in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Results From EPCORE NHL-2
Clinical Lymphoma Myeloma & Leukemia·2024
Autophagy in cancer resistance: New combinatorial strategy for cancer therapy
Leukemia·2024· 4 cited
Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: Updated results from EPCORE NHL-2.
Journal of Clinical Oncology·2024· 3 cited
page 1 of 14Next →

Frequent Co-authors

Daniel Olive(22), Françoise Mallet(8), Danielle Sainty(6), Jean‐Albert Gastaut(6), Christine Arnoulet(5), Charles M. Norris(5), Marshall R. Posner(5), Carole Sanchez(5), Mårina Lafage‐Pochitaloff(4), Cyril Fauriat(4), A. Dimitrios Colevas(4), Roy B. Tishler(4), D Sainty(4), Céline Baier(4), Laure Farnault(4), Thérèse Le Treut(4), G Sébahoun(4), Jean Imbert(4), Julien Mozziconacci(3), Arnon I. Dreyfuss(3)